← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Acute Hepatitis C Virus Infection

MONDO:0100371 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 50 citations openscientist · 66 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Acute (recently acquired) hepatitis C is the early phase of HCV infection, generally the first ~6 months after exposure, before either spontaneous clearance or establishment of chronic infection (defined by persistence of viremia beyond 6 months).

UNANIMOUS INTEGRATED
prognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 95% Acute (recently acquired) hepatitis C is the first ~6 months after HCV exposure, a period during which infection may spontaneously clear but still frequently progresses to chronic hepatitis C (persistent viremia >6 months).
Falcon states the 6-month acute-phase definition and the >6-month viremia criterion for chronicity directly.
DOI:10.3390/v16111739, DOI:10.3350/cmh.2022.0349
openscientist CONCORDANT 95% Acute Hepatitis C Virus Infection is defined as the first 6 months following initial HCV exposure and infection, characterized by detectable HCV RNA in the blood, with or without symptoms, and prior to the establishment of chronic infection.
OpenScientist gives the same first-6-months definition and adds the detectable-HCV-RNA characterization.

The natural history of acute HCV bifurcates: roughly 50-70% of untreated infections progress to chronicity while approximately 30-50% clear spontaneously, with wide variation by population and case definition.

UNANIMOUS INTEGRATED
prognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 85% one review emphasizes **~50–70%** progress to chronic infection (viremia >6 months).
Falcon reports the ~50-70% progression-to-chronicity figure and elsewhere notes the heterogeneity of clearance/progression estimates across reviews.
DOI:10.3390/v16111739
openscientist CONCORDANT 90% Approximately 50-70% of individuals with recently acquired hepatitis C will develop a chronic infection, defined as the persistence of viremia for a period exceeding six months
OpenScientist gives the identical 50-70% chronicity range with the >6-month viremia definition and pairs it with a 30-50% spontaneous-clearance rate.
PMID:39599853

The acute phase is predominantly asymptomatic (about 70-80% of cases), which limits early detection.

UNANIMOUS INTEGRATED
phenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 85% About **80%** of acute infections are asymptomatic.
Falcon reports ~80% of acute infections are asymptomatic and that many incident infections are clinically silent.
DOI:10.3350/cmh.2022.0349
openscientist CONCORDANT 90% The acute phase is predominantly asymptomatic (70-80% of cases), which severely limits early detection, though symptomatic patients presenting with jaundice have significantly higher rates of spontaneous viral clearance.
OpenScientist gives the 70-80% asymptomatic proportion and links symptomatic (icteric) presentation to higher clearance.

The IFNL3/IFNL4 (IL28B) rs12979860 CC genotype is the strongest host genetic predictor of spontaneous HCV clearance.

MAJORITY INTEGRATED
genetic_factorprognosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% The strongest host genetic predictor of spontaneous clearance is the IFNL3/IFNL4 (IL28B) polymorphism at rs12979860, where the CC genotype is associated with clearance with an odds ratio of 14.22 (P<0.0001).
OpenScientist names rs12979860 CC as the single strongest predictor and quantifies it (OR 14.22).
PMID:24445571
falcon PARTIAL 55% IL28B/IFNL3 genotypes rs12979860 CC and rs8099917 TT
Falcon lists the IL28B/IFNL3 rs12979860 CC genotype among factors favoring spontaneous clearance but does not rank it as the strongest predictor or give the OR — supporting the association without the quantitative claim.
DOI:10.3350/cmh.2022.0349

HCV evades innate immunity via its NS3/4A serine protease, which cleaves and inactivates the adaptor proteins MAVS and TRIF, disabling RIG-I/MAVS and TLR3/TRIF interferon-induction signaling.

SINGLE INTEGRATED
pathophysiologygene_function
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% the HCV NS3/4A protease can efficiently cleave and inactivate two important signalling molecules in the sensory pathways that react to HCV pathogen-associated molecular patterns (PAMPs) to induce IFNs, i.e., the mitochondrial anti-viral signalling protein (MAVS) and the Toll-IL-1 receptor-domain-containing adaptor-inducing IFN-beta (TRIF)
OpenScientist details the NS3/4A cleavage of both MAVS and TRIF as the core innate-immune-evasion mechanism.
PMID:25443342
falcon SILENT —
Falcon's guideline/clinically oriented report covers the high-level clearance-vs-persistence causal chain and T-cell immunity but does not address the NS3/4A protease or its MAVS/TRIF cleavage mechanism.

Pan-genotypic direct-acting antiviral regimens — notably glecaprevir/ pibrentasvir (8 weeks) and sofosbuvir/velpatasvir — achieve very high sustained virological response (SVR ~96-100%) in acute HCV.

MAJORITY INTEGRATED
treatment
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% Pan-genotypic regimens such as glecaprevir/pibrentasvir and sofosbuvir/velpatasvir achieve sustained virological response (SVR) rates of 96-100% in acute HCV infection with short treatment durations (8 weeks).
OpenScientist gives the same regimens with quantified SVR 96-100% and short durations, backed by the largest phase IIIb acute-HCV DAA trial.
PMID:41297677
falcon PARTIAL 60% glecaprevir/pibrentasvir for 8 weeks** and **sofosbuvir/velpatasvir for 12 weeks
Falcon names the same simplified regimens and durations for acute infection but frames them through guideline pathways without quantifying the 96-100% SVR rates.
DOI:10.21037/tgh-23-104

Guidelines endorse a "test-and-treat" approach: confirmed acute HCV should be treated the same as chronic infection rather than waiting for spontaneous clearance, and abbreviated 6-week DAA courses are not recommended.

MAJORITY INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 95% persons with **confirmed acute HCV infection (HCV RNA positive)** should be treated **the same as chronic HCV** and **should not wait for spontaneous clearance**.
Falcon states the AASLD-IDSA 2023 test-and-treat principle explicitly, including that abbreviated 6-week regimens are not recommended.
DOI:10.21037/tgh-23-104
openscientist PARTIAL 55% DAA therapy achieves near-100% cure, preventing chronic disease and onward transmission (treatment as prevention strategy)
OpenScientist endorses immediate treatment upon diagnosis as treatment-as-prevention but does not articulate the guideline specifics of treating acute the same as chronic, not waiting, or rejecting 6-week courses.

No preventive HCV vaccine currently exists; the virus's high genetic diversity (and, historically, limited animal models) is a central barrier to vaccine development and elimination.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 85% No prophylactic HCV vaccine is currently available**, and major scientific obstacles include HCV genetic diversity and limited animal models.
Falcon states no prophylactic vaccine is available and names genetic diversity and limited animal models as obstacles.
DOI:10.3350/cmh.2022.0349
openscientist CONCORDANT 85% the absence of a preventive vaccine remains the most critical gap in global HCV elimination efforts
OpenScientist calls the absence of a vaccine the most critical elimination gap and lists high genetic diversity and lack of immunocompetent small animal models among the reasons.

Acute HCV remains a major global burden, with on the order of 1.5 million (up to ~2 million) new infections per year worldwide.

UNANIMOUS LEAD
epidemiology
ProviderStanceScoreEvidence
falcon CONCORDANT 80% WHO estimates of **~1.5 million newly acquired HCV infections in 2019**
Falcon cites WHO estimates of ~1.5 million newly acquired HCV infections in 2019 with regional breakdowns.
DOI:10.3350/cmh.2022.0349
openscientist CONCORDANT 80% estimated 1.5-2 million new infections globally per year
OpenScientist gives an overlapping 1.5-2 million new infections/year estimate and adds the post-2015 reversal in age-standardized incidence.
PMID:42007346

Narrative

Overview

Both providers frame acute hepatitis C as the first ~6 months after HCV exposure — a largely asymptomatic, self-limited-or-persistent phase whose central question is spontaneous clearance versus progression to chronic infection. Falcon (Edison Scientific Literature) is guideline- and clinically-oriented, anchored on diagnostic windows, natural-history definitions, risk groups, and AASLD-IDSA treatment principles. OpenScientist (autonomous) is broader and more mechanistic, spanning viral entry, innate immune evasion, host genetics, DAA efficacy data, epidemiology, and model systems.

Agreement

The reports converge on the core clinical picture: the 6-month acute-phase definition and >6-month viremia criterion for chronicity; ~70-80% of acute infections being asymptomatic; roughly 50-70% progression to chronicity with ~30-50% spontaneous clearance; the favorable role of IFNL3/IL28B rs12979860 CC and HLA class II alleles in clearance; the transformative near-cure efficacy of pan-genotypic DAAs (glecaprevir/pibrentasvir, sofosbuvir/ velpatasvir) with short courses; the absence of any preventive vaccine as the key elimination barrier; and a global burden on the order of 1.5 million new infections per year.

Divergence

The two reports are complementary rather than contradictory. OpenScientist supplies molecular depth that Falcon omits entirely — the HCV entry-factor cascade and the NS3/4A protease cleavage of MAVS and TRIF as the innate-immune evasion mechanism, quantified clearance predictors (OR 14.22 for IL28B CC), detailed DAA SVR data, and model-organism systems. Falcon supplies guideline granularity OpenScientist only gestures at — the explicit test-and-treat principle (treat acute the same as chronic, do not wait for spontaneous clearance) and the recommendation against abbreviated 6-week regimens. Quantitative differences are minor (e.g., ~80% vs 70-80% asymptomatic; ~1.5 million in 2019 vs 1.5-2 million per year) and reflect framing/source choice, not conflict.

Integration

The convergent, well-supported claims map directly onto the existing kb/disorders/Acute_Hepatitis_C_Virus_Infection.yaml entry: the acute-vs-chronic definition and natural-history bifurcation, the asymptomatic-majority phenotype, the IFNL3/IL28B clearance genetics, the NS3/4A innate-evasion pathophysiology node, DAA treatment with high SVR, the test-and-treat principle, and the no-vaccine prevention gap.

Not integrated (leads)

Broader breadth-only material was retained as research leads rather than promoted: detailed global/regional epidemiology and incidence trends, model organism and cell-culture systems, extrahepatic/secondary organ involvement, special-population treatment nuances, and reinfection/access considerations. Provider-specific citation trails (no PMID/DOI overlap between the two reports) are preserved as prioritization cues for curator follow-up, not as conflicts.

Cross-provider synthesis comparing falcon (guideline/clinical, pathophysiology template) and openscientist (comprehensive, mechanism-rich) deep-research reports for acute HCV. No direct contradictions were found; divergence is coverage/emphasis (OpenScientist adds molecular entry/NS3-4A and quantified data; Falcon adds explicit test-and-treat guideline detail) plus minor quantitative framing differences. best_matching_text values are verbatim excerpts from the cited report files (some Falcon quotes retain the source markdown bold markers). Literature evidence blocks are intentionally omitted pending fetch-reference verification in the main curation pipeline.